AI and data ownership reshape pharma marketing: DeepIntent’s Jay Richetelli weighs in

Jay Richetelli, VP of Client Partnerships at DeepIntent, shares how artificial intelligence (AI) is transforming pharma marketing. He breaks down how generative Al is revolutionizing the creative process with tailored messaging, while predictive AI enhances audience targeting with real-time decisions based on syndicated data. Richetelli emphasizes that Al is not replacing marketers but empowering them to work more efficiently and effectively across siloed systems by unifying data, platforms and execution.

Looking ahead, Richetelli predicts a shift toward greater data ownership and control by pharma companies,  enabling deeper insights and faster, more strategic decision-making. He also stresses the importance of trust, privacy and compliance—areas in which DeepIntent has been a pioneer with HIPAA-safe, healthcare-specific Al solutions. For a deeper dive into these insights and to hear why data portability and audience optimization are becoming essential, be sure to watch the full interview.